D J Martin1, I Angel, S Arbilla
1Internal Medicine Research, Synthélabo Recherche, Rueil-Malmaison, France.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Functional uroselectivity in benign prostatic hyperplasia treatment is key. Alpha1-adrenoceptor subtype selectivity doesn't predict this, suggesting other mechanisms like the alpha1L-adrenoceptor may be involved.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: